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Abstract
Background: We highlight a chronic inflammatory disease we call 'hyper-IgG4 disease', which has
many synonyms depending on the organ involved, the country of origin and the year of the report.
It is characterized histologically by a lymphoplasmacytic inflammation with IgG4-positive cells and
exuberant fibrosis, which leaves dense fibrosis on resolution. A typical example is idiopathic
retroperitoneal fibrosis, but the initial report in 2001 was of sclerosing pancreatitis.
Methods: We report an index case with fever and severe systemic disease. We have also reviewed
the histology of 11 further patients with idiopathic retroperitoneal fibrosis for evidence of IgG4-
expressing plasma cells, and examined a wide range of other inflammatory conditions and fibrotic
diseases as organ-specific controls. We have reviewed the published literature for disease
associations with idiopathic, systemic fibrosing conditions and the synonyms: pseudotumour,
myofibroblastic tumour, plasma cell granuloma, systemic fibrosis, xanthofibrogranulomatosis, and
multifocal fibrosclerosis.
Results: Histology from all 12 patients showed, to varying degrees, fibrosis, intense inflammatory
cell infiltration with lymphocytes, plasma cells, scattered neutrophils, and sometimes eosinophilic
aggregates, with venulitis and obliterative arteritis. The majority of lymphocytes were T cells that
expressed CD8 and CD4, with scattered B-cell-rich small lymphoid follicles. In all cases, there was
a significant increase in IgG4-positive plasma cells compared with controls. In two cases, biopsies
before and after steroid treatment were available, and only scattered plasma cells were seen after
treatment, none of them expressing IgG4. Review of the literature shows that although pathology
commonly appears confined to one organ, patients can have systemic symptoms and fever. In the
active period, there is an acute phase response with a high serum concentration of IgG, and during
this phase, there is a rapid clinical response to glucocorticoid steroid treatment.
Conclusion: We believe that hyper-IgG4 disease is an important condition to recognise, as the
diagnosis can be readily verified and the outcome with treatment is very good.
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While investigating a patient who had an uncharacterised
multisystem disease with evidence of a severe acute-phase
response, we found that similar rare cases had been
described, usually as single reports [1], under an alarming
list of synonyms [2] (Table 1). These conditions are all
characterised by chronic inflammation leading to dense
fibrosis, and retroperitoneal fibrosis (RPF) is a typical
example. The principal synonyms that we found for these
fibrosing conditions are: pseudotumour, myofibroblastic
tumour, plasma cell granuloma, systemic fibrosis, xan-
thofibrogranulomatosis, and multifocal fibrosclerosis
(Table 1). As can be seen in Tables 1 and 2, these condi-
tions, such as RPF, Reidel's thyroiditis and sclerosing pan-
creatitis, are usually localised to one or two organs but can
present with systemic multisystem disease.
In another patient, we observed the rare behaviour of idi-
opathic RPF behaving like a tumour, in which the inflam-
matory mass was invading both the kidney and liver and
presented as a progressive cholangitis. This case was one
of a series of patients seen in our gastroenterological
department, who had sclerosing pancreatitis and chronic
inflammation associated with immunoglobulin (Ig)G4-
expressing plasma cells [3,4]. In biopsies from both these
cases, we found typical fibrosis with lymphoplasmacytic
inflammation and IgG4-bearing plasma cells [5].
Sclerosing (autoimmune) pancreatitis is a unique form of
pancreatitis, characterized by hypergammaglobulinaemia
and a lymphoplasmacytic inflammation of the pancreas
that responds to glucocorticoid treatment. It has several
synonyms (Table 2). A Japanese group investigating this
condition [6] found that the sera of their patients had a
polyclonal band in the rapidly migrating fraction of gam-
maglobulins, which was caused by a high concentration
of the IgG4 gammaglobulin fraction. They also reported
that serum concentrations of IgG4 were significantly and
specifically raised in patients with sclerosing pancreatitis,
and were closely associated with disease activity [6].
The same Japanese group found that of the 22 patients
with sclerosing pancreatitis they studied, three also had
concomitant hydronephrosis caused by a periureteric
mass, diagnosed as RPF (Ormond's disease). Histological
examination of the periureteric tissue showed abundant
infiltration of IgG4-bearing plasma cells. Treatment with
corticosteroids lowered serum concentrations of IgG4,
and the authors proposed that IgG4 might have a patho-
logical role in a systemic fibrosing process that includes
pancreatic and retroperitoneal lesions [5].
Kamisawa et al have also published several reports
emphasising the systemic nature of this process. Patients
with autoimmune pancreatitis may also have involve-
ment of lymph nodes and salivary glands as well as local
tissues [7,8], in a pattern suggestive of multifocal fibro-
sclerosis [9,10].
We describe our index case, and report on the histological
features of 11 other patients seen at our hospital with idi-
opathic RPF, for whom we have now been able to review
the histology and examine sections for evidence of IgG4-
expressing plasma cells. We also list the synonyms and
disease associations that we believe are all part of the same
disease process.
Methods
Histological examination
We report on the histological features of 16 biopsy speci-
mens from 12 patients seen at the Middlesex hospital with
a primary diagnosis of RPF, for whom we have now been
Table 1: Systemic fibrosis synonyms
Pseudotumour, inflammatory pseudotumour, 
fibrous pseudotumour
Systemic[83-85] Lung[86-89], liver[87,90-93], breast[94], pancreas[83,95-99], 
orbit[100], RPF[98-101], mesentery[102]
Inflammatory myofibroblastic tumour, 
myofibroblastoma
Systemic Pancreas[96], lung[46,103,104], brain[105], breast[106]
Plasma cell granuloma Systemic lung[107,108], brain[107]
Systemic fibrosis, generalized form of 
Ormond's disease, systemic idiopathic fibrosis, 
idiopathic systemic sclerosing disease
Systemic[1,109-111] PRF[109,111-113], orbit[112], lung[114,115]
Xanthofibrogranulomatosis, xanthogranuloma Systemic[1,2,116,117] RPF[101,118-121], brain[118,122], orbit[123]
Multifocal fibrosclerosis, multifocal idiopathic 
fibrosclerosis
Systemic[84,85,124-128] RPF[124,125,128-133], orbit[124,129-131,134] 
thyroid[127,128,132,133], pancreas[9]
RPF, retroperitoneal fibrosis.Page 2 of 18
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dence of IgG4-expressing plasma cells. Only archival par-
affin wax-embedded material was used for this study. All
the biopsies were taken for diagnostic reasons with the
informed consent of patients.
All the samples were routinely fixed in formalin and
embedded in paraffin wax. Dewaxed sections (μm) were
stained with haematoxylin and eosin. Immunohisto-
chemical analysis was performed using antibodies (all
Dako UK Ltd, Cambridgeshire, UK) against CD3, CD4,
CD8, CD20, and CD138, and the kappa and lambda light
chains of immunoglobulins, by the standard streptavidin-
biotin-peroxidase method. For IgG4, a mouse human
IgG4 monoclonal antibody was used (1:100 dilution,
MC011; The Binding Site, Birmingham, UK). Negative
controls were created by substituting the primary anti-
body with similarly diluted non-immunized mouse
serum.
We examined a wide variety of other inflammatory condi-
tions and fibrotic diseases as organ-specific controls,
which included liver (autoimmune hepatitis, chronic hep-
atitis C), pancreas (chronic and alcoholic pancreatitis),
salivary gland (chronic sialadenitis), gallbladder (chronic
cholecystitis), kidney (tubulointerstitial nephritis), duo-
denum (chronic duodenitis), colon (non-specific colitis),
and other fibrotic processes (Dupuytren's, keloid scars).
Because an association between RPF and asbestos expo-
sure has been reported [11], we also included cases of
malignant mesotheliomas. In addition, specimens from
cases of "benign pleural plaques" were stained as controls.
Positive controls comprised tissue obtained from pan-
creas, salivary gland and liver from patients seen in our
gastroenterological department who had sclerosing pan-
creatitis and chronic inflammation associated with IgG4-
expressing plasma cells, details of which have been
reported previously [3,4].
The degree of inflammation was assessed as severe [>100
inflammatory cells per high power field (), moderate (30–
100 cells/HPF) and mild (30–10 cells/HPF). The presence
of lymphoid-follicle formation, eosinophilic infiltration,
venulitis and obliterative arteritis (on elastic van Gieson-
stained sections) was also recorded. The number of IgG4-
Table 2: Conditions associated with systemic fibrosis
Name Synonyms
RPF Ormond's disease Systemic[109,111,113,135], 
lung[32,32,53,115,136,136,137], liver[138], 
breast, pancreas[5,139-141],
Retro-orbital tumour Fibrous pseudotumour of the orbit, Graves' 
orbitopathy
RPF[124,129-131,142-145]
Riedel's thyroiditis RPF[132,133,146-148] 
MFF[127,128,147,149,150]
Chronic sclerosing sialadenitis[151] Kuttner's tumour
Panniculitis Weber-Christian syndrome steatonecrosis, 
necrosing panniculitis
Systemic[110], RPF[135,152-155] Biliary 
cirrhosis[156], pancreas[157]
Sclerosing pancreatitis[158] Primary inflammatory pancreatitis (P)[159], 
lymphoplasmacytic sclerosing P[7,160,161], 
autoimmune P[162], sclerosing 
pancreaticocholangitis[163], pancreatic 
pseudo-tumour[95]
RPF[5,97,139,161,164,165], 
cholangitis[95,160,164,166,167], 
systemic[83,168-171] gastric ulcer[172], 
lung[173,174] panniculitis[157], 
mesentery[175]
Sclerosing cholangitis MFF[128], pancreas[92,166]
Bronchiolitis obliterans with organizing 
pneumonia
Cryptogenic organizing pneumonia, pulmonary 
hyalinizing granuloma.
Systemic[50,176], pancreas[173,174], 
liver[177], RPF[115,136,137], renal[46,136], 
mediastinum[178,179]
Benign pleural mesothelioma[180,181], 
calcifying pseudotumour[182,183]
Asbestos-related? RPF[11,26-28,32,32] peritoneum[56,184,185] 
pleura[54,55,186]
RPF, retroperitoneal fibrosis; MFF, multifocal fibrosclerosisPage 3 of 18
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ing as follows: 0 (no IgG4 plasma cells/HPF), 1 (≤ 20
cells/HPF), 2 (20–50 cells/HPF) or 3 (≥ 50 cells/HPF)
[12]. Fibrosis was assessed as - (no fibrosis), + (mild), ++
(moderate) or +++ (severe).
Literature review
We reviewed the published literature for disease associa-
tions with idiopathic, systemic fibrosing conditions using
the following synonyms: pseudotumour, myofibroblastic
tumour, plasma cell granuloma, systemic fibrosis, xan-
thofibrogranulomatosis and multifocal fibrosclerosis. We
also looked for reports associating these conditions with
organ-specific conditions, particularly sclerosing pancrea-
titis (see Table 2 for other synonyms), RPF, Reidel's thy-
roiditis, panniculitis, Weber-Christian syndrome and
retro-orbital tumour, and with a range of autoimmune
diseases (Table 3).
Many of these reports are case reports. We have not
attempted to list every report but rather to draw up a com-
prehensive list of all possible associations with at least one
citation.
Results
Index case
A 39-year-old Moroccan steel fitter had lived in the UK for
31 years. He presented in May 2003 with abdominal pain,
weight loss, sweating, generalized lymphadenopathy, and
severe anaemia and thrombocytosis. Investigations
showed haemoglobin of 6.7 g/dL (normal range 13.0–
17.0 g/dL), platelets 1031 × 109/L (150–400 × 109/L),
erythrocyte sedimentation rate (ESR) 120 mm/h (0–15
mm/h), IgG 21.4 g/L (8.0–18.0 g/L), IgA 2.9 g/L (0.9–4.5
g/L), IgM 0.6 g/L (0.6–2.8 g/L) and C-reactive protein
(CRP) 289 mg/L (normal 0–5 mg/L). Biochemistry was
normal. Chest X-ray showed apical pleural thickening. An
intravenous urogram (IVU) showed left hydronephrosis;
an ultrasound scan (USS) confirmed this, and showed dil-
atation of the bile and pancreatic ducts and the gallblad-
der. Computed tomography (CT) showed multifocal
upper zone and patchy nodular airspace shadowing, with
right posterior pleural thickening and subcarinal lym-
phadenopathy. Biopsies of pleural, ileal and colonic tis-
sue, bone marrow, and left inguinal lymph node were all
either normal or showed reactive change. Cultures of
blood, urine and sputum were all negative. The patient
was also negative for human immunodeficiency virus
types 1 and 2, hepatitis B and C, human T-lymphotropic
virus, toxoplasmosis and treponemal disease. Mantoux
test was weakly positive, and although bronchoalveolar
lavage was smear-negative, there was one positive culture
for a mycobacterium after 3 weeks.
The patient was commenced on quadruple therapy for
tuberculosis (TB) in July 2003, for an organism that was
strongly isoniazid-resistant. The patient presented again
in November with fatigue, weight loss and fever, which
was thought to be medication-related. He was given pred-
nisolone 20 mg for 6 weeks of, taken off all TB therapy,
and after 2 months was feeling so well that he was told his
TB had been cured.
He re-presented 3 months later (March 2004) with a 6-
week history of night sweats, low-grade fever, lethargy,
weight loss, left pleuritic chest pain and axillary lymphad-
enopathy. Blood tests again showed microcytic anaemia,
and the same acute phase response. Antinuclear antibody
(ANA), antineutrophil cytoplasmic antibodies, mitochon-
drial antibodies and smooth-muscle antibodies were all
negative. CT showed many of the previous changes but
with a right hydronephrosis that was confirmed on IVU
(left hydronephrosis was no longer present). A repeat
bone-marrow biopsy, inguinal lymph node and transjug-
ular liver biopsies, endoscopy, colonoscopy, peritoneal
fluid aspiration and bone scan were all either normal or
non-specific. The patient was treated with quintuple anti-
TB therapy in order to cover his original mycobacterium
infection as well as an infection with Mycobacterium fortu-
itum that had been cultured from sputum on this occa-
sion. He was also treated with steroids, initially 60 mg of
prednisolone, tapered down to 20 mg over 3 months.
The patient was readmitted 6 months later with general-
ized abdominal pain and vomiting. He had stopped his
steroids 11 days earlier because of side effects. Investiga-
tions showed only a marked inflammatory response. CT
scan revealed no hydronephrosis, but now showed
dilated, thick-walled small bowel in the left iliac fossa.
During an exploratory laparotomy (October 2004), an
inflamed omental mass adherent to the small-bowel
mesentery was removed. Histology was reported as show-
ing only some fibrosis with a mild chronic inflammatory
cell infiltrate of lymphocytes and plasma cells. The patient
was recommenced on steroids and quadruple anti-TB
therapy.
He remained well for some months, but then presented
(March 2005) with a 6-week history of pain in the right
upper quadrant of the abdomen. His blood tests showed
the same inflammatory response and a USS showed
prominent intrahepatic ducts only. The histology of the
omental mass was reviewed and showed a large number
of IgG4-positve plasma cells throughout the fibroinflam-
matory reaction (Table 4). The patient's serum IgG con-
centration was 21.4 g/l and IgG4 2.4 (normal range 0–1.3
g/l). A diagnosis of hyper-IgG4 disease was made, all
microbial therapy was stopped, and the patient was
treated with prednisolone 20 mg/day with immediatePage 4 of 18
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Table 3: Rare associations with IgG4-related conditions (Case reports)
Head and neck
Submandibular gland fibrosis Pancreas[95], cholangitis[187,188], pseudotumour[189]
Parotid involvement pancreas[171]
Sjögren's syndrome Pancreas[171,190], RPF[164], BOOP[191]
Maculopathy MFF[126]
Uveitis RPF[192]
Conjunctiva Pseudotumour[86]
Hashimoto's disease, Graves' disease RPF[193]
Cardiovascular
Constrictive pericarditis RPF[194]
Heart valves RPF[20,22]
Mediastinal fibrosis RPF[194-196]
Chronic periaortitis/aneurysm RPF[197-205]
Vasculitis RPF[125,206,207]
Occlusive phlebitis MFF[149]
Intermittent claudication RPF[208]
Rheumatology
Rheumatoid arthritis BOOP[176], RPF[209]
Polymyalgia rheumatica BOOP[210]
Ankylosing spondylitis RPF[211]
Periarticular fibrosis RPF[212]
Skeletal hyperostosis RPF[213]
Dermatomyositis Pseudotumour[88], BOOP[214]
Polymyositis BOOP[191,215]
Scleroderma RPF[216]
Other autoimmune conditions
Systemic lupus erythematosus RPF[217]
Idiopathic thrombocytopenic purpura RPF[218,219]
Haemolytic anaemia Lung[220], cholangitis[221]
Central nervous system
Brain PCG[107], xanthogranuloma[118,222]
Sella MFF[124,126]
Spinal cord compression RPF[223]
Gastrointestinal
Primary biliary cirrhosis RPF[224], BOOP[176]
Mesentery RPF[112,152,175,225], pseudotumour[102,153,155]
Bladder/pelvic mass RPF[49,208,226,227]
Duodenal obstruction RPF[228,229]
Portal hypertension RPF[230]
Others
Familial multifocal fibrosclerosis Familial RPF MFF[43] RPF[42]
Proliferative crescentic glomerulonephritis, membranous 
glomerulonephritis
RPF[231] RPF[232]
Interstitial nephritis Pancreas[233]
Testicular involvement RPF[126,234]
MFF, multifocal fibrosclerosis; RPF, retroperitoneal fibrosis; BOOP, bronchiolitis obliterans with organizing pneumonia; PCG, plasma-cell 
granuloma.
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and 5 mg prednisolone.
Pathology of IgG4 disease
We reviewed the histology and examined sections for evi-
dence of IgG4-expressing plasma cells of 16 biopsies from
12 patients with a clinical diagnosis of idiopathic RPF
seen at our hospital in the past 10 years. Biopsies com-
prised nine samples of retroperitoneal tissue, two of liver,
and one each from kidney, colon and omentum. In addi-
tion, there were two further samples of retroperitoneal tis-
sue taken from two patients after steroid therapy.
The results are shown in Table 4. All patients showed, to
varying degrees, fibrosis, intense inflammatory cell infil-
tration with lymphocytes, plasma cells, scattered neu-
trophils and in some cases eosinophilic aggregates. The
majority of lymphocytes expressed CD8 and CD4 positiv-
ity (T-cell markers), with B cells present to a lesser degree
and with scattered B-cell-rich small lymphoid follicles. In
addition, we saw vasculitis affecting small veins, and evi-
dence of obliterative arteritis (Figures 1, 2, 3). In all cases,
there was a significant increase in IgG4-positive plasma
cells compared with controls (Figure 4). Even when few
plasma cells were seen (patients 10–12) the majority
expressed IgG4 (Figure 5). In two cases, biopsies before
and after steroid treatment were available; only scattered
plasma cells were seen after treatment, none of which
expressed IgG4 (Fig 3). In all of our patients, the kappa
and lambda light chains showed a polytypic pattern. We
used PCR to look for evidence of oligoclonal infiltrates for
IgH in one case (patient 1), as has been reported from
Japan [13], but found none. None of the wide range of
control sections showed significantly increased numbers
of IgG4-positive cells.
We also examined biopsy specimens from liver (two
patients), large bowel (one) and renal tissue (one). In all
of them, we found mild fibrosis and a small increase in
lymphoplasmacytic inflammatory cell infiltrate, although
IgG4-positive plasma cells were not seen in one liver
biopsy, nor in the colon biopsy (Table 4).
In summary, raised numbers of IgG4-positive plasma cells
are seen in both peritoneal and non-peritoneal tissues in
patients with hyper-IgG4 disease. The degree of IgG4-pos-
itive staining did not necessarily correlate with elevated
serum IgG. Our clinical impression was that the number
of IgG4-positive plasma cells was associated with disease
activity.
Discussion
RPF is probably the most common example of the condi-
tions associated with raised serum IgG4 and an IgG4-pos-
itive plasma cell infiltrate, which we call hyper-IgG4
diseases. The other most frequently recognised associa-
tions are sclerosing pancreatitis, Reidel's thyroiditis, retro-
orbital tumour, panniculitis, and sclerosing cholangitis
(see Table 2 for synonyms).
It is known that RPF can be associated with a similar
fibrotic process in other organs, particularly adjacent tis-
sues such as the mediastinum and pleura. Patients with
RPF can have systemic symptoms and be febrile. We used
RPF and our knowledge of its aetiology and pathogenesis
to review the potential mechanisms of IgG4 disease.
Table 4: Histopathology
Patient no., sex, age Organ Fibrosis* Lymphoplasmacytic
infiltrate†
Lymphoid follicles Venulitis Eosinophilic
component
IgG4-positive
plasma cells‡
(1) Male, 52 Kidney +++ +++ Yes No No 3
Liver ++ + No No Yes 0
(2) Male, 73 Retroperitoneum +++ +++ Yes Yes Yes 3
(3) Male, 39 Omentum + ++ Yes No No 3
(4) Male, 53 Retroperitoneum +++ +++ Yes Yes Yes 3
(5) Male, 45 Periureter +++ +++ Yes Yes No 2
(6) Female, 58 Retroperitoneum +++ +++ No Yes No 3
(7) Female, 55 Para-aortic tissue +++ +++ Yes Yes No 3
(8) Male, 47 Periureter tissue +++ + Yes Yes No 2
(9) Male, 48 Retroperitoneum +++ ++ No No No 2
(10) Male, 73 Retroperitoneum +++ +++ Yes Yes Yes 1
(11) Female, 56 Retroperitoneum +++ ++ Yes No No 1
(12) Male, 53 Liver ++ + No No No 1
Colon ++ + No No No 0
*Degree of interstitial fibrosis: +, mild; ++, moderate; +++, severe fibrosis.
†Degree of inflammation: +++ (severe), >100 inflammatory cells/HPF; ++ (moderate), 30–100 cells/HPF; + (mild), 10–30 cells/HPF
‡IgG4-positive plasma cells: 0, no IgG4 plasma cells/high power field (HPF); 1, ≤ 20 cells/HPF), 2, 20–50 cells/HPF; 3, ≥ 50 cells/HPF (criteria of Aoki 
et al [12]).Page 6 of 18
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Idiopathic RPF generally presents in a non-specific man-
ner with malaise, fatigue, fever and weight loss [11,14-
16]. Pain in the back (lumbosacral) region, flank or lower
abdomen is most common. The pathognomonic feature
of RPF is a thick retroperitoneal fibrotic mass covering the
abdominal aorta and compressing the ureters. The process
of fibrosis can result in obstruction of the ureters and
renal failure, or signs and symptoms may be related to the
encasement or entrapment of other structures by the
inflammatory mass, such as hydrocoeles or unilateral leg
oedema. With renal involvement, severe hypertension is
common.
The disease presents typically between the ages of 50 and
70 years, and men are affected 2–3 times more commonly
than women [14]. The inflammatory nature of idiopathic
RPF is demonstrated by elevated ESR and CRP, reduced
haemoglobin and elevated gammaglobulins at presenta-
tion. An autoimmune nature is suggested by the finding of
ANA in 10–20% of cases, an occasional association with
different autoimmune diseases and good response to glu-
cocorticosteroids. In one series of RPF associated with
periaortitis, 10 of 16 patients were ANA-positive [17].
Although there are no randomised studies of treatment
for RPF, patients who present during the acute inflamma-
tory phase respond quickly to glucocorticosteroids.
Patients with late presentation and dense fibrosis will not
respond to medical treatment and surgery is often neces-
sary[11].
Causes and associations
RPF has many causes, although in about 70% of cases the
cause is unknown (idiopathic). The rest (secondary)
develop as a result of malignant disease, radiation ther-
Mesenteric massFigure 1
Mesenteric mass. Patient 3 (index case): (a, b) fibrosis, lymphoid aggregates and plasma cells (haematoxylin and eosin (a) × 
100, (b) ×400); (c) CD138-positive plasma cells; (d) IgG4-positive plasma cells.Page 7 of 18
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haemorrhage, urine extravasation, and infections. Carci-
noid syndrome can cause systemic fibrosis [18], and RPF
has been described without metastatic tumour [19].
Drugs
RPF has also been associated with the use of several drugs,
but most commonly the ergotamine derivates, especially
methysergide [20] and, more recently, those used as
dopamine agonists to treat Parkinson's disease, such as
pergolide and cabergoline [21].
From an aetiological perspective, drugs associated with
RPF are important as they also cause fibrosis in various
other sites. Systemic fibrosis is a prominent feature of
methysergide use, with involvement of heart and lungs,
particularly heart valves [20,22]. A similar distribution of
pathology has been reported with the dopamine agonists
pergolide and cabergoline [23-25].
Of pathogenetic importance is the observation that with-
drawal of these offending drugs usually results in a rapid
improvement in symptoms, reduction in inflammatory
markers and regression of pathology [20]. Drug-induced
cases are not associated with ANA [16].
Asbestos
Recently, asbestos exposure has been proposed as a causal
factor for both pleural and retroperitoneal fibrosis [11,26-
28]. Asbestos fibres also cause interstitial lung fibrosis
(asbestosis), pleural fibrosis, pleural plaques, lung cancer,
and pleural and peritoneal mesothelioma [29]. Patients
exposed to asbestos, and particularly those with asbesto-
sis, have an increased incidence of ANA and other autoan-
tibodies, and raised levels of IgG and IgA. There is also a
correlation between the degree of immunological abnor-
mality and the likelihood of progression [30,31].
A case-control study in Finland of 43 patients with RPF
(86% of eligible cases) found that the age-standardised
incidence of RPF was 0.10 per 100000 person-years [11].
For every patient, five population-based matched controls
were selected. There was a strong association with asbes-
tos exposure. The odds ratio (OR) was 5.5 for <10 fibre-
years of asbestos exposure and 8.8 for ≤ 10 fibre-years.
Other risk factors were previous use of ergot derivates (OR
= 9.92), abdominal aortic aneurysm (OR = 6.73) and
smoking for >20 pack-years (OR = 4.73) [11].
We also saw pleural calcification in three of our patients
with RPF, in whom it was not present at the presentation
of the illness. One of those cases is included in our archi-
val review (patient 5, Table 4). This raises the question of
whether some of the pleural pathology associated with
IgG4 disease can heal with calcification as well as fibrosis
[32].
Aortitis
The relationship of aortic aneurysms with an inflamed
and thickened aortic wall, extensive periaortal inflamma-
tion and RPF is well known [33]. As the inflammatory
aneurysms of the abdominal aorta differ from RPF only in
the diameter of the inflamed aorta, it has been suggested
that both syndromes represent only variations of the same
disease, which has been named 'chronic periaortitis' [34].
RPF has been suggested as the most severe form of chronic
periaortitis [35,36]. Vasculitis of the vasa vasorum was
thought to be a factor in the aneurysmal dilatation
[34,37].
Renal biopsyFigure 2
Renal biopsy. Patient 1, showing renal involvement. (a) 
Cores of renal tissue with a conspicuous component of inter- 
and intra-tubular inflammatory cells (haematoxylin and eosin 
×100); (b) IgG4-positive plasma cells.Page 8 of 18
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esis for this periaortitis. As well as the periaortal tissue, the
media and adventitia of the aorta are infiltrated by poly-
clonal B lymphocytes, activated CD4-positive T lym-
phocytes, and plasma cells [35]. In 85% of patients, the
necrotic media contains deposits of IgG antibodies in
close proximity to extracellular ceroid, and the serum
often contains antibodies against ceroid and oxidised
low-density lipoprotein [38].
Although it was initially proposed that the aortitis was
caused by an autoimmune response to the components of
atherosclerotic plaques [38] with antibodies to atheroma,
more recent opinion has suggested that in view of the
accompanying systemic symptoms and acute phase
response, the aortitis is a primary autoimmune disease
[17,36,39,40].
Autoimmune and other rare associations
While there is no one predominant association, a large
range of autoimmune diseases has been described in asso-
ciation with RPF (Table 3), and 10–20% of cases will have
ANA or other autoantibodies.
Paediatric
RPF in the paediatric population is rare with, only 23 cases
reported in the English-language literature by 2003 [41].
A family has been reported in which two children had idi-
opathic retroperitoneal fibrosis, and they and their father
had clinical and laboratory evidence of systemic immuno-
logical diseases [42].
Familial
Two brothers from a first-cousin consanguineous mar-
riage were reported, who had different combinations of
Retroperitoneal tissueFigure 3
Retroperitoneal tissue. Patient 7. Pre-glucocorticoid treatment: (a) fibrosis and plasma cells (haematoxylin and eosin ×400); 
(b) IgG4-positive plasma cells. Post-glucocorticoid treatment: (c) scattered CD138-positive plasma cells; (d) IgG4 staining 
reveals no positive cells.Page 9 of 18
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sclerosing thyroiditis, and pseudotumour of the orbit.
One of the brothers had fibrotic contracture of the fingers
[43]. Other reports are of RPF in three siblings with sickle-
cell trait [44], and mediastinal and retroperitoneal fibrosis
in two sisters with seronegative spondyloarthropathy
[45].
RPF invading adjacent organs
Rarely, the inflammatory tissue seen in RPF can invade the
renal parenchyma [46-48] and it can occasionally cause a
tumour-like mass away from the retroperitoneum [49].
There are four isolated surgical case reports in the litera-
ture, with two being described as idiopathic RPF, one as
systemic hyalinizing granuloma and the other as xanthofi-
brogranuloma. We have seen one case in which the IgG4-
positive inflammatory mass (Figure 2) invaded the kidney
and liver (patient 1, Table 4), and another in which it
caused a large tumour like mass in the left iliac fossa
(patient 2). Both cases responded promptly to steroids.
Summary
Although all our archival cases of idiopathic RPF have
shown evidence of IgG4 involvement, it remains to be
seen whether IgG4 plays any role in other types of RPF
such as periaortitis, drug-induced and asbestos-related
RPF. We certainly found it (in retroperitoneal tissue) in
one of our patients who developed pleural calcification.
Histopathology: IgG4 immunostaining (cases versus controls)Figure 4
Histopathology: IgG4 immunostaining (cases versus controls). Vertical axis (0–120) shows number of IgG4-positive 
plasma cells/high power field (see Methods for details). Histological data from salivary gland is positive control, (from previ-
ously reported study [3,4]).
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Part of the spectrum of disease in patients with hyper-
IgG4 disease is parenchymal lung pathology, often
described as either bronchiolitis obliterans with organiz-
ing pneumonia or cryptogenic organizing pneumonia
[50]. This is seen typically as migratory pulmonary infil-
trates, and is steroid-responsive. Nevertheless, there are at
present no studies that have looked for evidence of IgG4
plasma cells in these conditions [51]. Other conditions
associated with migratory pulmonary infiltrates that may
be related, but not yet investigated, include pulmonary
eosinophilia, hypersensitivity to drugs, parasitic infection,
allergic bronchopulmonary aspergillosis and Churg-
Strauss vasculitis [52]. Pleural thickening, with and with-
out calcification, is well described [32,32,53]. There are
also reports of calcifying pseudo-tumour of the pleura
[54,55] and peritoneum [56].
Differential diagnosis of febrile illness
Fever of unknown origin (FUO) in an immunocompetent
patient is defined as an illness of more than 3 weeks' dura-
tion with fever higher than 38.3°C (101°F) on several
occasions, and with an uncertain diagnosis after 1 week of
investigation [57]. Infection accounts for about one-third
of cases (25–32%) of FUO, followed by non-infectious
inflammatory disease (21–31%) and neoplasm (12–
17%) [58-62]. Although many patients with FUO will be
found to have bacterial infection, rarer diagnoses will be
considered with time and extensive investigation. Never-
theless, at the end of all investigations, 18–30% of
Percentage of IgG4-bearing plasma cellsFigure 5
Percentage of IgG4-bearing plasma cells.
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this idiopathic group will improve spontaneously [60].
We propose that hyper-IgG4 disease can be added to this
list of systemic inflammatory diseases.
Pathogenesis
Conditions associated with elevated IgG4
IgG4 is the rarest of the IgG subclasses to be expressed,
accounting for only 3–6% of total IgG in normal serum. It
has a low affinity for target antigen. It is unique among the
IgG subclasses, as it is unable to bind Clq complement
and cannot activate the classic complement pathway [63].
IgG4 is a T-helper 2 (Th2)-dependent isotype. Interleukin
(IL)-4 directs naive human B cells to switch to IgG4 and
IgE production [64]; IL-10 and IL-13 are the other T-cell-
derived cytokines that activate this differentiation.
High serum IgG4 concentrations are found in a limited
number of other conditions, including atopic dermatitis
[65], some parasitic diseases (helminthic diseases) [66],
and pemphigus vulgaris (PV) and pemphigus foliaceus
(PF)[67,68].
In allergic individuals, a feature of successful immuno-
therapy is the induction of allergen-specific IgG4 antibod-
ies, even with the persistence of allergen-specific IgE
[69,70]. High levels of the immunosuppressive cytokine
IL-10 are found both in patients chronically infected with
helminths and in those receiving allergen immuno-
therapy [71]. IL-10 also stimulates IgG4 production [72].
Th2 responses to allergens are suppressed by both CD4+
CD25+ T regulatory cells (Tregs) and IL-10-producing
Tregs [73], and suppression by these subsets is decreased
in allergic individuals. In animal models, Tregs can be
induced by high- or low-dose inhaled antigen, and prior
induction of Tregs prevents subsequent development of
allergen sensitization and airway inflammation in inhaled
challenge models. Allergen-injection immunotherapy
may induce IL-10 Tregs, leading to both suppression of
Th2 responses and a switch from IgE to IgG4 antibody
production [73].
Helminths
Asymptomatic infections with helminth parasites are cor-
related with high levels of IgG4, and parasite-specific IgG4
antibodies can inhibit IgE-mediated degranulation of
mast cells [66]. In most helminth infections, the Th2
response leads to rapid parasite expulsion or sequestra-
tion. During murine Schistosoma mansoni infection, how-
ever, parasites persist and the chronic Th2 response can
induce severe pathological fibrosis in the gut and liver
[74]. Evidence both from these mouse models and from
human studies suggests that this progression to severe dis-
ease with intense fibrosis occurs in only a minority of
cases, and is a consequence of the strongly profibrotic type
2 cytokine response mediated by IL-4 and IL-13 [74].
Pemphigus and pemphigoid
PV and PF are autoimmune skin diseases caused by
autoantibodies against desmoglein 3 and desmoglein 1
respectively. These antibodies are predominantly of the
IgG4 subclass [67,68]. Desmogleins are keratinocyte
transmembrane proteins localized in the desmosome,
and are members of the adhesion molecule family of cad-
herins. The interaction of antidesmoglein antibodies with
their target antigens leads to loss of cell adhesion (acan-
tholysis) and the formation of intraepithelial blisters of
the skin and mucous membranes. The antibodies pre-
dominantly, but not exclusively, bind to the extracellular
domains of the proteins and exert their pathogenic effect
not through inhibition of the proteins' adhesive proper-
ties, but through an indirect pathway involving cellular
signalling pathways, resulting in destabilization of des-
moglein 1-based adhesive sites and desmosomes [75].
Bullous pemphigoid (BP) is an autoimmune blistering
disease associated with autoantibodies against the
hemidesmosomal glycoprotein BP180. The noncollagen-
ous (NC)16A domain of BP180 has major antigenic sites
recognized by BP sera. IgG4 and IgE are the major immu-
noglobulins that preferentially react with two distinct
epitopes within this domain. Levels of these autoantibod-
ies correlated with disease activity in BP [76].
Autoimmune pancreatitis
In sclerosing pancreatitis, evidence had been reported to
suggest an immunological pathogenesis even before the
description of a role for IgG4. In one study of 17 patients,
ANA and antilactoferrin antibodies were detected in 76%,
carbonic anhydrase II antibody in 59%, rheumatoid fac-
tor in 29% and anti-smooth-muscle antibody in 18% of
patients. CD8+ and CD4+ cells were significantly
increased in peripheral blood. CD4+ cells produced
increased levels of interferon gamma compared with con-
trols, but IL-4 was not increased [77]. However, in another
Japanese study, which divided patients with sclerosing
pancreatitis into a seronegative and seropositive group,
found no differences in presentation, pathology or natural
history between the groups [78].
HLA associations with IgG4-associated diseases
• PV was consistently found to be associated with DR4
and DR14 and, more precisely, with DRB1*0402 and
DRB1*1401 subtypes [79]. Susceptibility to PF has been
correlated with the presence of DR4, DR14 and DR1 alle-
les; however, in contrast to PV, no single DR4 or DR14
allele was shown to be associated with the disease.Page 12 of 18
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mune pancreatitis, a significant increase in DR4 was
found. It was concluded that the DRB1*0405-
DQB1*0401 haplotype was associated with autoimmune
pancreatitis in the Japanese population [80].
• Aortoarteritis is a chronic inflammatory disease, mainly
affecting the aorta and its major branches. In a Chinese
Han population, the DRB1*04 and DRB1*07 alleles were
significantly associated with aortoarteritis. Furthermore,
there was no significant difference in the frequency of the
DRB1*0405 subtype between the patient and control
groups [81].
• In China, the HLA-DRB5*0101 allele and the IL-13 pro-
moter A/A genotype were both found to be elevated in
schistosomal hepatic fibrosis, although the two genes are
located on different chromosomes. Subjects with both
genotypes had odds ratios much higher (OR = 24.5) than
the sum of the ratios for each individual genotype. The
study strongly suggested that a pathogenic Th2 response
directly influenced the prognosis of post-schistosomal
liver fibrosis[82].
Conclusion
We believe that hyper-IgG4 disease is an important condi-
tion to recognise as the diagnosis can be verified by histol-
ogy and simple blood tests, and the outcome with
treatment during the acute phase is very good. A raised
IgG concentration in the absence of hypergammaglobuli-
naemia is typical, but ideally IgG4 should also be meas-
ured. Even when pathology appears localised, as with
RPF, constitutional symptoms can be present with evi-
dence of an acute phase response. Rarely a systemic form
of the disease will present with severe constitutional
symptoms, and hyper-IgG4 disease can be added to list of
unusual causes of FUO. Although the role and relevance
of IgG4 is unknown, the dense fibrosis that accompanies
healing would appear to be a typical example of Th2-
mediated pathology.
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